cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ac Immune Sa
48 own
32 watching
Current Price
$3.92
$0.01
(0.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
326.96M
52-Week High
52-Week High
5.14000
52-Week Low
52-Week Low
2.20000
Average Volume
Average Volume
0.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.8528
iconMarket Capitalization326.96M
icon52-Week High5.14000
icon52-Week Low2.20000
iconAverage Volume0.21M
iconDividend Yield--
iconP/E Ratio9.8528
What does the Ac Immune Sa do?
AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.
Read More
News & Events about Ac Immune Sa.
Globe Newswire
1 year ago
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 Lausanne, Switzerland, July 3, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimers ...
Globe Newswire
1 year ago
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimers disease (AD) cohort in ABATE Phase 1b/2 trial;Further ABATE immunogenicity and safety data in higher dose AD ...
Globe Newswire
1 year ago
AC Immune at AD/PD 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimers & Parkinsons Diseases (AD/PDTM)AC Immunes Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimers ...
Globe Newswire
1 year ago
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for ...
Globe Newswire
1 year ago
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will ...
Frequently Asked Questions
Frequently Asked Questions
What is Ac Immune Sa share price today?
plus_minus_icon
Can Indians buy Ac Immune Sa shares?
plus_minus_icon
How can I buy Ac Immune Sa shares from India?
plus_minus_icon
Can Fractional shares of Ac Immune Sa be purchased?
plus_minus_icon
What are the documents required to start investing in Ac Immune Sa stocks?
plus_minus_icon
What is today’s traded volume of Ac Immune Sa?
plus_minus_icon
What is today’s market capitalisation of Ac Immune Sa?
plus_minus_icon
What is the 52-Week High and Low Range of Ac Immune Sa?
plus_minus_icon
What percentage is Ac Immune Sa down from its 52-Week High?
plus_minus_icon
What percentage is Ac Immune Sa up from its 52-Week Low?
plus_minus_icon
Current Price
$3.92
$0.01
(0.2%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00